Mpox Cases Rise in Brazil: Symptoms, Prevention & 2026 Update

Berlin, Germany – A recent surge in mpox cases in Brazil, coupled with the first confirmed case in Jundiaí, São Paulo state, in 2026, is prompting renewed public health vigilance. While the current outbreak appears less severe than the widespread transmission experienced in 2022 and 2025, health officials are closely monitoring the situation and urging continued preventative measures. The rise in cases underscores the ongoing necessitate for awareness and proactive strategies to mitigate the spread of this viral disease.

Brazil’s Ministry of Health reported 88 confirmed mpox cases as of March 3, 2026, a significant increase from the 48 cases reported on February 20, 2026. This rapid escalation has triggered a heightened response from public health authorities, who are working to identify and contain potential outbreaks. The majority of these cases are concentrated in São Paulo, with 62 confirmed infections, followed by Rio de Janeiro (15), Rondônia (4), Minas Gerais (3), Rio Grande do Sul (2), the Federal District (1) and Paraná (1). The situation highlights the importance of robust surveillance systems and rapid response capabilities in managing infectious disease outbreaks.

Understanding Mpox: Transmission, Symptoms, and Prevention

Mpox, formerly known as monkeypox, is a viral disease caused by the monkeypox virus, which belongs to the orthopoxvirus family – the same family as smallpox. The virus spreads primarily through close contact with skin lesions and scabs, bodily fluids, and respiratory droplets during prolonged face-to-face interaction. Contaminated objects, such as clothing, bedding, or towels, can also serve as vectors for transmission. Understanding these transmission routes is crucial for implementing effective prevention strategies.

Symptoms of mpox typically begin with a fever, headache, muscle aches, and swollen lymph nodes. This is followed by the development of a rash that can appear on the face, hands, feet, mouth, or genitals. The rash progresses through distinct stages, from macules (flat spots) to papules (raised bumps), vesicles (fluid-filled blisters), and finally, pustules (pus-filled blisters) that eventually scab over. While most patients experience mild to moderate illness, some may develop more severe complications, particularly individuals with weakened immune systems. Early recognition of symptoms and prompt medical attention are essential for managing the disease and preventing further spread.

Brazil’s Mpox Experience: A Look at Recent Trends

The current increase in mpox cases in Brazil follows a significant outbreak in 2025, which saw 1,079 confirmed cases and two deaths. This represents a substantial increase compared to the 215 cases recorded in 2024. The recent jump in cases, while concerning, has not yet resulted in any fatalities in 2026, according to the Ministry of Health. Though, the rapid rise underscores the potential for renewed transmission and the need for sustained public health efforts.

The concentration of cases in São Paulo and Rio de Janeiro suggests that these urban centers may be experiencing higher rates of transmission. This could be attributed to factors such as population density, increased social mixing, and potentially, lower vaccination rates. Further investigation is needed to determine the specific drivers of transmission in these regions and to tailor interventions accordingly.

Global Context and Ongoing Concerns

While Brazil is currently experiencing a notable increase in mpox cases, the multi-country outbreak extends beyond its borders. A recent situation report from the Pan American Health Organization (PAHO), dated February 27, 2026, indicates that a total of eight countries in the Americas have reported cases in 2026: Argentina, Bolivia, Brazil, Canada, Chile, Colombia, Mexico, and the United States. This regional spread highlights the interconnectedness of global health and the importance of international collaboration in controlling infectious diseases.

The PAHO report emphasizes the need for continued surveillance, testing, and contact tracing to effectively manage the outbreak. Vaccination remains a key preventative measure, particularly for individuals at higher risk of exposure. However, access to vaccines may be limited in some regions, posing a challenge to widespread immunization efforts. Addressing vaccine equity and ensuring equitable access to healthcare resources are crucial for mitigating the impact of the outbreak.

Is There a Cure for Mpox? Treatment and Management

Currently, there is no specific cure for mpox. Treatment focuses on managing symptoms and preventing complications. Antiviral medications, such as tecovirimat (TPOXX), have been authorized for use in some countries, but their effectiveness is still being evaluated. Supportive care, including pain management, wound care, and fluid replacement, is essential for helping patients recover. Researchers continue to investigate potential therapeutic options and to develop more effective treatments for mpox.

A researcher interviewed by ND Mais emphasized that while there isn’t a definitive cure, the disease is generally self-limiting, meaning it resolves on its own with appropriate care. However, individuals with weakened immune systems or underlying health conditions may be at higher risk of severe complications and require more intensive medical management. Prompt diagnosis and access to healthcare are crucial for ensuring optimal outcomes.

Preventative Measures and Public Health Recommendations

Preventing the spread of mpox requires a multi-faceted approach that includes individual precautions and public health interventions. Individuals can reduce their risk of infection by avoiding close contact with individuals who have symptoms, practicing good hygiene (including frequent handwashing), and avoiding sharing personal items such as clothing, bedding, and towels. Safe sexual practices, including the use of condoms, can also help reduce the risk of transmission.

Public health authorities recommend vaccination for individuals at higher risk of exposure, including healthcare workers, laboratory personnel, and individuals with multiple sexual partners. Contact tracing and isolation of confirmed cases are also essential for containing outbreaks. Public awareness campaigns can help educate the public about mpox, its symptoms, and preventative measures. Sustained investment in public health infrastructure and research is crucial for preparing for and responding to future outbreaks.

The situation in Jundiaí, with the confirmation of the first case in 2026, serves as a reminder that mpox remains a public health concern. Continued vigilance, proactive prevention measures, and robust surveillance systems are essential for protecting communities and mitigating the impact of this viral disease.

Health officials will continue to monitor the situation closely and provide updates as new information becomes available. The next key update from the Brazilian Ministry of Health is expected in early April 2026. Readers are encouraged to share this information with their networks and to consult with healthcare professionals if they have any concerns about mpox.